Head to Head Comparison: GeneLink (OTCMKTS:GNLKQ) versus Aclarion (NASDAQ:ACON)

Aclarion (NASDAQ:ACON) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Insider and Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. 22.3% of Aclarion shares are held by insiders. Comparatively, 14.2% of GeneLink shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Aclarion and GeneLink, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	0	0	1	0	3.00
GeneLink	0	0	0	0	N/A

Aclarion presently has a consensus target price of $1.50, suggesting a potential upside of 747.46%.

Valuation and Earnings

This table compares Aclarion and GeneLink”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$53,947.00	26.91	-$4.91 million	N/A	N/A
GeneLink	N/A	N/A	N/A	N/A	N/A

GeneLink has lower revenue, but higher earnings than Aclarion.

Volatility and Risk

Aclarion has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, GeneLink has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500.

Profitability

This table compares Aclarion and GeneLink’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,967.15%	-910.84%	-218.13%
GeneLink	N/A	N/A	N/A

Summary

Aclarion beats GeneLink on 5 of the 8 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.